Advertisement


Related Videos

Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”

Breast Cancer

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.

Breast Cancer

Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”

Breast Cancer

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.

Advertisement

Advertisement




Advertisement